4//SEC Filing
Aunins John G. 4
Accession 0000899243-18-002334
CIK 0001609809other
Filed
Jan 29, 7:00 PM ET
Accepted
Jan 30, 9:01 PM ET
Size
11.1 KB
Accession
0000899243-18-002334
Insider Transaction Report
Form 4
Aunins John G.
CTO and EVP of Bioprocess Dev.
Transactions
- Exercise/Conversion
COMMON STOCK
2018-01-26+5,000→ 200,502 total - Sale
COMMON STOCK
2018-01-26$11.02/sh−1,738$19,153→ 198,764 total - Exercise/Conversion
RESTRICTED STOCK UNITS
2018-01-26−5,000→ 20,000 total→ COMMON STOCK (5,000 underlying) - Award
STOCK OPTION (RIGHT TO BUY)
2018-01-30−40,000→ 40,000 totalExercise: $10.42Exp: 2028-01-29→ COMMON STOCK (40,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020.
- [F3]The Option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Documents
Issuer
Seres Therapeutics, Inc.
CIK 0001609809
Entity typeother
Related Parties
1- filerCIK 0001643756
Filing Metadata
- Form type
- 4
- Filed
- Jan 29, 7:00 PM ET
- Accepted
- Jan 30, 9:01 PM ET
- Size
- 11.1 KB